Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Acta Diabetologica
Erschienen in:

01.05.2020 | Original Article

Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease

verfasst von: Tasnim Alkayyali, Lubna Qutranji, Eda Kaya, Alev Bakir, Yusuf Yilmaz

Erschienen in: Acta Diabetologica | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Background/aim

Simple noninvasive fibrosis scores based on routine blood tests have been increasingly investigated as screening tools in different clinical settings. Here, we sought to examine whether the Fibrosis-4 Index (FIB-4) and the non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS) could perform differently in diabetic versus non-diabetic patients with biopsy-proven NAFLD.

Methods

We examined 349 patients with biopsy-proven NAFLD (166 with type 2 diabetes and 183 without). Patients with FIB-4 scores < 1.3 and  > 2.67 or NFS scores < − 1.455 and  > 0.676 were considered at low and high risk of advanced fibrosis, respectively.

Results

A FIB-4 cutoff value of 1.3—which denotes a low risk of advanced fibrosis—had a specificity of 67% in patients with diabetes and 69% in those without. Conversely, a FIB-4 cutoff value of 2.67—which denotes a high risk of advanced fibrosis—had a sensitivity of 22% in patients with diabetes and 0% in those without. NFS performed similar to FIB-4.

Conclusion

Both FIB-4 and NFS scores have an acceptable clinical utility in the exclusion of advanced fibrosis in patients with NAFLD, regardless of the presence of type 2 diabetes. However, their usefulness in identifying advanced fibrosis is limited—especially in the absence of diabetes.
Literatur
1.
Chalasani N, Younossi Z, Lavine JE, et al. (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67:328–357CrossRef
2.
3.
Younossi Z, Tacke F, Arrese M, et al. (2019) Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Hepatology 69:2672–2682CrossRef
4.
Dai W, Ye L, Liu A, et al. (2017) Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis. Medicine (Baltimore) 96:e8179CrossRef
5.
6.
Li Q, Dhyani M, Grajo JR, et al. (2018) Current status of imaging in nonalcoholic fatty liver disease. World J Hepatol 10:530–542CrossRef
7.
Stål P (2015) Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. World J Gastroenterol 21:11077–11087CrossRef
8.
Morling JR, Fallowfield JA, Guha IN, et al. (2014) Edinburgh type 2 diabetes study investigators. Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study. J Hepatol 60:384–391CrossRef
9.
Sanyal AJ, Brunt EM, Kleiner DE, et al. (2011) Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 54:344–353CrossRef
10.
American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1):S62–S69CrossRef
11.
12.
Shah AG, Lydecker A, Murray K, et al. (2009) Nash clinical research network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 7:1104–1112CrossRef
13.
Angulo P, Hui JM, Marchesini G, et al. (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:846–854CrossRef
14.
Bedossa P, Poitou C, Veyrie N, et al. (2012) Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 56:1751–1759CrossRef
15.
Kleiner DE, Brunt EM, Van Natta M, et al. (2005) Nonalcoholic steatohepatitis clinical research network. Nonalcoholic steatohepatitis clinical research network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313–1321CrossRef
16.
Richards JA (2013) Remote sensing digital image analysis: an introduction, 5th edn. Springer, Berlin
17.
Guha IN, Parkes J, Roderick P, et al. (2008) Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 47:455–460CrossRef
18.
McPherson S, Anstee QM, Henderson E, et al. (2013) Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? Eur J Gastroenterol Hepatol 25:652–658CrossRef
19.
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388–402.
20.
Angulo P, Kleiner DE, Dam-Larsen S, et al. (2015) Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149:389–397CrossRef
21.
Ekstedt M, Hagström H, Nasr P, et al. (2015) Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61:1547–1554CrossRef
22.
Singh S, Allen AM, Wang Z, et al. (2015) Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13:643–654CrossRef
23.
Alkhouri N, Lawitz E, Noureddin M (2019) Looking into the crystal ball: predicting the future challenges of fibrotic NASH treatment. Hepatol Commun 3:605–613CrossRef
24.
Cheah MC, McCullough AJ, Goh GB (2017) Current modalities of fibrosis assessment in non-alcoholic fatty liver disease. J Clin Transl Hepatol 5:261–271PubMedPubMedCentral
25.
Friedrich-Rust M, Ong MF, Martens S, et al. (2008) Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 134:960–974CrossRef
26.
Wong VW, Vergniol J, Wong GL, et al. (2010) Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 51:454–462CrossRef
Metadaten
Titel
Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease
verfasst von
Tasnim Alkayyali
Lubna Qutranji
Eda Kaya
Alev Bakir
Yusuf Yilmaz
Publikationsdatum
01.05.2020
Verlag
Springer Milan
Erschienen in
Acta Diabetologica / Ausgabe 5/2020
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-019-01467-7

Weitere Artikel der Ausgabe 5/2020

One-year follow-up of ischemic index changes after intravitreal dexamethasone implant for diabetic macular edema: an ultra-widefield fluorescein angiography study

  • Original Article

Diabetic retinopathy, diabetic macular edema, and cardiovascular risk: the importance of a long-term perspective and a multidisciplinary approach to optimal intravitreal therapy

  • Review Article

Circulating mitochondrial DNA is decreased in children and adolescents with obesity and/or insulin resistance

  • Short Communication

Successful allogeneic islet transplantation after total pancreatectomy with islet autotransplantation to restore normoglycemia: a case report

  • Case Report

The novel loss of function Ile354Val mutation in PPARG causes familial partial lipodystrophy

  • Original Article

Self-care activities adherence in Tunisian patients with type 2 diabetes: role of diabetes-related distress and self-efficacy

  • Letter to the Editor

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Fortgeschrittenes Melanom: Wann den Checkpoint-Inhibitor absetzen?

Eine ICI-Therapie sollte bei Betroffenen mit fortgeschrittenem Melanom mindestens ein Jahr fortgesetzt werden. Bei anhaltendem Ansprechen kann danach offenbar ohne hohes Risiko ein Therapieabbruch erwogen werden.

Therapiestopp bei älteren MS-Kranken kann sich lohnen

Eine Analyse aus Kanada bestätigt: Setzen ältere MS-Kranke die Behandlung mit Basistherapeutika ab, müssen sie kaum mit neuen Schüben und MRT-Auffälligkeiten rechnen.

Dank Nasenspray seltener in die Notaufnahme

Durch die intranasale Applikation von Etripamil lassen sich paroxysmale supraventrikuläre Tachykardien (PSVT) oft in Eigenregie beenden. Das erspart den Betroffenen das Aufsuchen von Notfallambulanzen.

Vorhofflimmern: So häufig kommt es bei Katheterablation zu Embolien

Arterielle Embolien – insbesondere Hirnembolien - sind eine mögliche periprozedurale Komplikation bei Katheterablation von Vorhofflimmern. Wie hoch ist das Risiko? Eine Analyse von weltweit mehr als 300.000 Ablationsprozeduren gibt darüber Auskunft.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise